PROBIOTIC CHEWABLE TABLET
Natural health product licensed in Canada
- Other names
- PROBIOTIC-10B CHEWABLE TABLET, PROBIOTICS CHEWABLE TABLET
- Licence holder
- Celex Laboratories Inc.
- NPN or DIN-HM
- 80083043
- Status
- Active licence
- Licence date
- 12 February 2018
- Revision date
- Not provided
- Form
- Comprimé, à croquer
- Route of administration
- Orale
- Application type
- Officinale
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Bifidobacterium breve Source : Strain B3 | 2 Milliards d'UFC | Not calculated |
| Bifidobacterium breve Source : Cellule entière | 2 Milliards d'UFC | Not calculated |
| Lactobacillus acidophilus Source : LAC-361 | 2 Milliards d'UFC | Not calculated |
| Lactobacillus acidophilus Source : Cellule entière | 2 Milliards d'UFC | Not calculated |
| Lactobacillus rhamnosus Source : En entier | 2 Milliards d'UFC | Not calculated |
| Lactobacillus rhamnosus Source : Strain LCS742 | 2 Milliards d'UFC | Not calculated |
| Lacticaseibacillus paracasei Source : Cellule entière | 2 Milliards d'UFC | Not calculated |
| Lacticaseibacillus paracasei Source : Strain LACShield | 2 Milliards d'UFC | Not calculated |
| Bifidobacterium longum subsp. longum Source : BB-536 | 2 Milliards d'UFC | Not calculated |
| Bifidobacterium longum subsp. longum Source : Cellule entière | 2 Milliards d'UFC | Not calculated |
Non-medicinal ingredients
Dioxyde de silicium colloïdal, Acide stéarique, Oligofructose, Dextrose, Inuline, Poudre de lait écrémé, Cellulose microcristalline, Sorbitol
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes, adolescents et enfants | minimum: 3 years | 1 Comprimé | minimum: 1 Tous les jours ; maximum: 2 Tous les jours |
Uses authorised in Canada
HELPS SUPPORT INTESTINAL/GASTROINTESTINAL HEALTH. COULD PROMOTE A FLAVORABLE GUT FLORA.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
If you have fever, vomiting, bloody diarrhoea or severe abdominal pain, consult a health care practitioner prior to use. If symptoms of digestive upset (e.g. diarrhea) occur, worsen, or persist beyond 3 days, discontinue use and consult a health care practitioner.
- Contre-indications
If you have an immune-compromised condition (e.g. AIDS, lymphoma, patients undergoing long-term corticosteroid treatment), do not use this product.
Source
Official Health Canada record, licence 80083043
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.